FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004200901> ?p ?o ?g. }

• W2004200901 endingPage "1200" @default.
• W2004200901 startingPage "1192" @default.
• W2004200901 abstract "3-Deazaadenosine (c3Ado) is a potent inhibitor of S -adenosylhomocysteine hydrolase, which regulates cellular methyltransferase activity. In the present study, we sought to determine the effect of c3Ado on vascular smooth muscle cell (VSMC) function and neointima formation in vivo. c3Ado dose-dependently prevented the proliferation and migration of human coronary VSMCs in vitro. This was accompanied by an increased expression of the cyclin-dependent kinase inhibitors p21 WAF1/Cip1 , p27 Kip1 , a decreased expression of G 1 /S phase cyclins, and a lack of retinoblastoma protein hyperphosphorylation. In accordance with these findings, fluorescence-activated cell-sorting analysis of propidium iodide–stained cells indicated a cell cycle arrest in the G 0 /G 1 phase. Importantly, c3Ado did not affect the number of viable (trypan blue exclusion) or apoptotic cells (TUNEL). Mechanistically, c3Ado prevented FCS-induced Ras carboxyl methylation and membrane translocation and activity by inhibiting isoprenylcysteine carboxyl methyltransferase and reduced FCS-induced extracellular signal-regulated kinase (ERK)1/2 and Akt phosphorylation in a dose-dependent manner. Conversely, rescuing signal transduction by overexpression of a constitutive active Ras mutant abrogated c3Ado’s effect on proliferation. For in vivo studies, the femoral artery of C57BL/6 mice was dilated and mice were fed a diet containing 150 μg of c3Ado per day. c3Ado prevented dilation-induced Ras activation, as well as ERK1/2 and Akt phosphorylation in vivo. At day 21, VSMC proliferation (proliferating-cell nuclear antigen [PCNA]-positive cells), as well as the neointima/media ratio (0.7±0.2 versus 1.6±0.4; P <0.05) were significantly reduced, without any changes in the number of apoptotic cells. Our data indicate that c3Ado interferes with Ras methylation and function and thereby with mitogenic activation of ERK1/2 and Akt, preventing VSMC cell cycle entry and proliferation and neointima formation in vivo. Thus, therapeutic inhibition of S -adenosylhomocysteine hydrolase by c3Ado may represent a save and effective novel approach to prevent vascular proliferative disease." @default.
• W2004200901 created "2016-06-24" @default.
• W2004200901 creator A5000330109 @default.
• W2004200901 creator A5004094283 @default.
• W2004200901 creator A5017189713 @default.
• W2004200901 creator A5048716653 @default.
• W2004200901 creator A5049240652 @default.
• W2004200901 creator A5051231892 @default.
• W2004200901 creator A5060390578 @default.
• W2004200901 creator A5073723425 @default.
• W2004200901 creator A5084888219 @default.
• W2004200901 creator A5084973486 @default.
• W2004200901 creator A5091729029 @default.
• W2004200901 date "2009-05-22" @default.
• W2004200901 modified "2023-10-16" @default.
• W2004200901 title "3-Deazaadenosine Prevents Smooth Muscle Cell Proliferation and Neointima Formation by Interfering With Ras Signaling" @default.
• W2004200901 cites W1487258982 @default.
• W2004200901 cites W1575136067 @default.
• W2004200901 cites W1970030465 @default.
• W2004200901 cites W1987430295 @default.
• W2004200901 cites W2003267467 @default.
• W2004200901 cites W2004799153 @default.
• W2004200901 cites W2022973051 @default.
• W2004200901 cites W2032296752 @default.
• W2004200901 cites W2032664222 @default.
• W2004200901 cites W2035363409 @default.
• W2004200901 cites W2041227486 @default.
• W2004200901 cites W2051056502 @default.
• W2004200901 cites W2082925412 @default.
• W2004200901 cites W2090033280 @default.
• W2004200901 cites W2106946250 @default.
• W2004200901 cites W2117889142 @default.
• W2004200901 cites W2125150503 @default.
• W2004200901 cites W2125362970 @default.
• W2004200901 cites W2147247409 @default.
• W2004200901 cites W2151426663 @default.
• W2004200901 cites W2165850593 @default.
• W2004200901 cites W250613533 @default.
• W2004200901 doi "https://doi.org/10.1161/circresaha.109.194357" @default.
• W2004200901 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19372464" @default.
• W2004200901 hasPublicationYear "2009" @default.
• W2004200901 type Work @default.
• W2004200901 sameAs 2004200901 @default.
• W2004200901 citedByCount "25" @default.
• W2004200901 countsByYear W20042009012012 @default.
• W2004200901 countsByYear W20042009012013 @default.
• W2004200901 countsByYear W20042009012014 @default.
• W2004200901 countsByYear W20042009012015 @default.
• W2004200901 countsByYear W20042009012016 @default.
• W2004200901 countsByYear W20042009012017 @default.
• W2004200901 countsByYear W20042009012018 @default.
• W2004200901 countsByYear W20042009012019 @default.
• W2004200901 countsByYear W20042009012020 @default.
• W2004200901 countsByYear W20042009012021 @default.
• W2004200901 countsByYear W20042009012022 @default.
• W2004200901 crossrefType "journal-article" @default.
• W2004200901 hasAuthorship W2004200901A5000330109 @default.
• W2004200901 hasAuthorship W2004200901A5004094283 @default.
• W2004200901 hasAuthorship W2004200901A5017189713 @default.
• W2004200901 hasAuthorship W2004200901A5048716653 @default.
• W2004200901 hasAuthorship W2004200901A5049240652 @default.
• W2004200901 hasAuthorship W2004200901A5051231892 @default.
• W2004200901 hasAuthorship W2004200901A5060390578 @default.
• W2004200901 hasAuthorship W2004200901A5073723425 @default.
• W2004200901 hasAuthorship W2004200901A5084888219 @default.
• W2004200901 hasAuthorship W2004200901A5084973486 @default.
• W2004200901 hasAuthorship W2004200901A5091729029 @default.
• W2004200901 hasBestOaLocation W20042009011 @default.
• W2004200901 hasConcept C11960822 @default.
• W2004200901 hasConcept C126322002 @default.
• W2004200901 hasConcept C134018914 @default.
• W2004200901 hasConcept C1491633281 @default.
• W2004200901 hasConcept C153911025 @default.
• W2004200901 hasConcept C184235292 @default.
• W2004200901 hasConcept C190283241 @default.
• W2004200901 hasConcept C2775934118 @default.
• W2004200901 hasConcept C2776062698 @default.
• W2004200901 hasConcept C2777339539 @default.
• W2004200901 hasConcept C2778283817 @default.
• W2004200901 hasConcept C2778308172 @default.
• W2004200901 hasConcept C2778583881 @default.
• W2004200901 hasConcept C2779395532 @default.
• W2004200901 hasConcept C29537977 @default.
• W2004200901 hasConcept C2992686903 @default.
• W2004200901 hasConcept C31573885 @default.
• W2004200901 hasConcept C55493867 @default.
• W2004200901 hasConcept C57074206 @default.
• W2004200901 hasConcept C62112901 @default.
• W2004200901 hasConcept C62478195 @default.
• W2004200901 hasConcept C71924100 @default.
• W2004200901 hasConcept C75217442 @default.
• W2004200901 hasConcept C86803240 @default.
• W2004200901 hasConcept C95444343 @default.
• W2004200901 hasConceptScore W2004200901C11960822 @default.
• W2004200901 hasConceptScore W2004200901C126322002 @default.
• W2004200901 hasConceptScore W2004200901C134018914 @default.
• W2004200901 hasConceptScore W2004200901C1491633281 @default.
• W2004200901 hasConceptScore W2004200901C153911025 @default.

• next